Evaluating von Willebrand factor and ADAMTS13 levels in thalassemia major patients and assessing a possible association with Thrombospondin‐1

Abstract

AbstractIntroductionAlterations in the endothelium and endothelial adhesion proteins such as von Willebrand factor (vWF) play major roles in hypercoagulability in thalassemia. vWF protein release leads to platelet aggregation and thrombi formation at the site of vascular injury. It is then degraded by the proteolytic enzyme ADAMTS13. Thrombospondin‐1 is a multifactorial glycoprotein, which was reported to compete with ADAMTS13 for sites of vWF proteolysis. In this study, levels of vWF, ADAMTS13, and TSP‐1 proteins were determined in β‐thalassemia major patients. A possible association between TSP‐1 and vWF and ADAMTS‐13 was also evaluated.MethodsThe study was conducted on 80 β‐thalassemia major patients and 80 age and sex matched healthy controls. The 80 patients were sub‐divided into two groups; splenectomised and non‐splenectomised. vWF, ADAMTS13 and TSP‐1 plasma level were measured using ELISA technique.ResultsThere was no significant difference in vWF and TSP‐1 levels between patients and controls (p > 0.05). However, ADAMTS13 levels and ADAMTS13 activity/vWF antigen ratio were significantly higher in patients compared to controls (p < 0.05). VWF antigen and TSP‐1 level were significantly higher in splenectomised patients (p = 0.025 and p < 0.001, respectively). We also observed a significant decrease in ADAMTS13 activity/vWF antigen ratio among splenectomised compared to non‐ splenectomised patients (p = 0.019). Correlation analysis showed a significant negative correlation between TSP‐1 and vWF Collagen Binding Activity (r = −0.394, p = 0.021) and a positive correlation with ADAMTS13 activity/vWF antigen ratio (r = 0.356, p = 0.039) in splenectomised compared to non‐ splenectomised patients.ConclusionOur findings highlight the adequacy of patient management protocols for β‐TM in Kuwait as patients presented with comparable levels of platelets, vWF and TSP‐1 compared to normal controls. The reported increase in ADAMTS13 in patients may be required to maintain normal levels of vWF. Although no active thrombotic episodes were reported at the time of the study, the significant rise in platelets, vWF:Ag and TSP‐1 levels in splenectomised patients may indicate a tendency towards hypercoagulability. Monitoring of splenectomised patients is recommended.